Levomepromazine Maleate Morningside Healthcare

Levomepromazine Maleate, the active ingredient in Levomepromazine Maleate Morningside Healthcare, is a phenothiazine antipsychotic presented as an oral formulation for oral use. It is employed to manage schizophrenia, other psychotic disorders, and severe nausea or vomiting that does not respond to conventional therapy.

GNH USA supplies Levomepromazine Maleate Morningside Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomepromazine Maleate is used within the phenothiazine antipsychotic class to treat several serious conditions.

- Schizophrenia: reduces psychotic symptoms such as delusions and hallucinations. - Psychotic disorders: controls acute agitation and behavioral disturbances. - Severe nausea and vomiting: provides antiemetic relief when other agents are ineffective.

Levomepromazine Maleate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Orthostatic hypotension - Dry mouth and other anticholinergic effects - Weight gain - Constipation - Blurred vision

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Agranulocytosis or severe leukopenia - Life‑threatening cardiac arrhythmias - Severe hypotension leading to syncope - Seizures - Tardive dyskinesia or other irreversible movement disorders

Before initiating therapy, clinicians should consider several safety measures.

- Blood pressure monitoring: watch for orthostatic drops. - Cardiac assessment: evaluate history of arrhythmias or QT prolongation. - CNS depression: avoid in patients with severe respiratory compromise. - Elderly patients: start at lower doses and monitor for falls. - Hepatic/renal function: adjust dosing if impairment is present. - Store at below 25°C: keep in the original pack, protect from moisture.

Levomepromazine Maleate can interact with a variety of medicines, requiring careful management.

Major Interactions (Avoid): - CNS depressants (e.g., opioids, benzodiazepines): increased sedation and respiratory depression. - Antihypertensive agents: additive hypotensive effect. - QT‑prolonging drugs (e.g., certain antiarrhythmics): heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): possible serotonin syndrome. - Alcohol: enhances sedative properties and may worsen hypotension.